Interpretation of WHO consolidated guidelines on tuberculosis Module 4: Treatment of drug-susceptible tuberculosis

doi:10.19982/j.issn.1000-6621.20220330

Chinese Journal of Antituberculosis ›› 2022, Vol. 44 ›› Issue (11): 1122-1125.doi: 10.19982/j.issn.1000-6621.20220330

• Interpretation of Standards • Previous Articles Next Articles

Interpretation of WHO consolidated guidelines on tuberculosis Module 4: Treatment of drug-susceptible tuberculosis

Yuan Yuan¹, Lu Shuihua²()

¹Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China
²National Clinical Research Center for Infectious Diseases/The Third People’s Hospital of Shenzhen/The Second Affiliated Hospital of Southern University of Science and Technology, Guangdong Province, Shenzhen 518112, China

Received:2022-08-29 Online:2022-11-10 Published:2022-11-03
Contact: Lu Shuihua E-mail:lushuihua66@126.com
Supported by:
Guangdong Clinical Research Center for Infectious Diseases (Tuberculosis)(2020B1111170014);Shenzhen Tuberculosis Clinical Medical Research Center (Shenzhen Science and Technology Innovation [2021]287)

Abstract

Abstract:

In 2010, World Health Organization (WHO) issued recommendations for the treatment of drug susceptible tuberculosis (DS-TB). This treatment regimen is widely used, but in clinical practice, it is found that many patients fail to complete the 6-month treatment due to the long treatment time. Based on two phase Ⅲ trials, for the first time, the 2022 WHO guidelines add to the evidence-based recommendations of the most recent 2021 guideline development panel, which recommended a 4-month regimen for DS-TB. In this article, the author interprets the treatment of DS-TB according to the latest 2022 guidelines.

Key words: Tuberculosis, pulmonary, Therapeutic uses, Consensus development conferences as topic

CLC Number:

R453
R521

Yuan Yuan, Lu Shuihua. Interpretation of WHO consolidated guidelines on tuberculosis Module 4: Treatment of drug-susceptible tuberculosis[J]. Chinese Journal of Antituberculosis, 2022, 44(11): 1122-1125. doi: 10.19982/j.issn.1000-6621.20220330

References 6

[1]	World Health Organization. Treatment of tuberculosis:guidelines for national programmes (4th Edition). Geneva: World Health Organization, 2010.
[2]	Dorman SE, Nahid P, Kurbatova EB, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med, 2021, 384(18): 1705-1718. doi: 10.1056/NEJMoa2033400. doi: 10.1056/NEJMoa2033400 URL
[3]	Chabala C, Turkova A, Thomason MJ, et al. Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial. Trials, 2018, 19(1): 237. doi: 10.1186/s13063-018-2608-5. doi: 10.1186/s13063-018-2608-5 pmid: 29673395
[4]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: Treatment. Drug-susceptible tuberculosis treatment. Geneva: World Health Organization, 2022.
[5]	World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care. Geneva: World Health Organization, 2017.
[6]	贺晓新, 李波, 周林. 《4个月含利福喷丁抗结核治疗方案疗效观察》解读. 中国防痨杂志, 2021, 43(12):1243-1247. doi: 10.3969/j.issn.1000-6621.2021.12.004. doi: 10.3969/j.issn.1000-6621.2021.12.004

[1]	National Clinical Research Centre for Infectious Disease/The Third People’s Hospital of Shenzhen, Peking University Shenzhen Hospital, Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis, Shenzhen Key Laboratory of Inflammatory and Immune Diseases. Expert consensus on diagnosis and treatment of latent tuberculosis infection in patients with rheumatic diseases [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 869-879.
[2]	XIA Hui, ZHENG Yang, SONG Yuan-yuan. Interpretation of the Optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis complex issued by World Health Organization [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 641-645.
[3]	TIAN Na, CHU Hong-qian, SUN Zhao-gang. Recent progress of Nano-drug delivery system for tuberculosis treatment [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 732-737.
[4]	The Joint Tuberculosis Professional Branch of Chinese Antituberculosis Association, The Western China Bone Tuberculosis Union, The North China Union of Bone Tuberculosis. Expert consensus on the diagnosis and treatment of Brucella spondylitis [J]. Chinese Journal of Antituberculosis, 2022, 44(6): 531-538.
[5]	AN Hui-ru, WU Xue-qiong. Interpretation of immunoadjuvant therapy in Expert consensus on immune function assessment and immunotherapy in patients with active tuberculosis (2021 Edition) [J]. Chinese Journal of Antituberculosis, 2022, 44(6): 539-543.
[6]	CHEN Zhi, LIANG Jian-qin. Expert consensus on nutritional assessment and nutritional support treatment for patients with severe tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 421-432.
[7]	SUN Zhao-gang. Attention should be paid to the research and development of Mycobacterium tuberculosis antigen detection technology [J]. Chinese Journal of Antituberculosis, 2022, 44(2): 120-124.
[8]	Gong Wenping, Mi Jie, Wu Xueqiong. Immunologically active substances: novel treatment options for tuberculosis and nontuberculous mycobacteriosis [J]. Chinese Journal of Antituberculosis, 2022, 44(11): 1107-1121.
[9]	Nie Wenjuan, Yang Yang, Shi Wenhui, Wang Jun, Liu Peiying, Wang Qingfeng, Chu Naihui. Treatment containing interleukin-2 may improve the early sputum culture negative conversion rate in newly diagnosed and drug-susceptible pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2022, 44(10): 1010-1015.
[10]	He Meiyan, Zhang Zunjing, Liu Zhongda. Study on clinical efficacy of integrated traditional Chinese and western medicine in the treatment of pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(10): 1037-1042.
[11]	Tuberculosis Control Branch of Chinese Antituberculosis Association, Elderly Tuberculosis Control Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for active screening of pulmonary tuberculosis in Chinese communities [J]. Chinese Journal of Antituberculosis, 2022, 44(10): 987-997.
[12]	Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment /Institute for Tuberculosis Research/Department of Tuberculosis of the 8th Medical Center of Chinese PLA General Hospital, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus on the rational use of glucocorticoids in tuberculosis treatment [J]. Chinese Journal of Antituberculosis, 2022, 44(1): 28-37.
[13]	Chinese Antituberculosis Association , National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention . Recommendations on pretomanid (PA-824) in the treatment of multidrug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(1): 38-44.
[14]	Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment/Institute for Tuberculosis Research of the 8th Medical Center of Chinese PLA General Hospital, Editorial Board of Chinese Journal of Antituberculosis , Basic and Clinical Speciality Committees of Tuberculosis Control Branch of China International Exchange and Promotive Association for Medical and Health Care . Expert consensus on immune function assessment and immunotherapy in patients with active tuberculosis (2021 Edition) [J]. Chinese Journal of Antituberculosis, 2022, 44(1): 9-27.
[15]	Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Chinese expert consensus on the all-oral treatment of drug-resistant pulmonary tuberculosis (2021 Edition) [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 859-866.

Interpretation of WHO consolidated guidelines on tuberculosis Module 4: Treatment of drug-susceptible tuberculosis

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 6

Related Articles 15

Recommended Articles

Metrics

Comments